Pharmacokinetic Profiles of Inhaled Lipid Complex Amphotericin B (Abelcet ®)

Phase 3 Completed 48 enrolled University of Pittsburgh Enzon Pharmaceuticals, Inc. · collab

Non-randomizedSingle-groupOpen-labelPrevention

Summary

The purpose of this study is to determine the optimal delivery system for the nebulization of the lipid complex amphotericin B (Abelcet ®) in lung transplant recipients who are positive for invasive aspergillosis (IA) in their lungs. Additionally, the investigators hope to determine the concentrations of amphotericin B achieved in the epithelial lining fluid, and serum with the administration of four days of lipid complex of amphotericin B (Abelcet ®) (QD) via aerosolized nebulization

Timeline

Start: 2004-09
Primary completion: —
Completion: 2005-09

Publications

Husain S, Capitano B, Corcoran T, Studer SM, Crespo M, Johnson B, Pilewski JM, Shutt K, Pakstis DL, Zhang S, Carey ME, Paterson DL, McCurry KR, Venkataramanan R. Intrapulmonary disposition of amphotericin B after aerosolized delivery of amphotericin B lipid complex (Abelcet; ABLC) in lung transplant recipients. Transplantation. 2010 Dec 15;90(11):1215-9. doi: 10.1097/TP.0b013e3181f995ea.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Amphotericin B	Unknown	1 mg/kg	Inhaled

Pharmacokinetic Profiles of Inhaled Lipid Complex Amphotericin B (Abelcet ®)

Summary

Timeline

Publications

Drugs

Indications